MCY-M11 + Cyclophosphamide
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Peritoneal Mesothelioma
Conditions
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
Trial Timeline
Aug 27, 2018 → Aug 24, 2021
NCT ID
NCT03608618About MCY-M11 + Cyclophosphamide
MCY-M11 + Cyclophosphamide is a phase 1 stage product being developed by MaxCyte for Peritoneal Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03608618. Target conditions include Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03608618 | Phase 1 | Terminated |
Competing Products
20 competing products in Peritoneal Mesothelioma